Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028949 | 0.80 | CFTR (0.32) | CFTREEDPTAFR | |
| SCHEMBL13435562 | 0.74 | KDM4E (0.33) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL9447795 | 0.70 | KDM4E (0.36) | KDM4EALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL9414994 | 0.70 | KDM4E (0.41) | KDM4EALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL11664211 | 0.70 | CFTR (0.38) | CFTR | |
| SCHEMBL11666012 | 0.70 | CFTR (0.38) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL11611852 | 0.69 | CFTR (0.34) | CFTR | |
| SCHEMBL5626323 | 0.69 | CFTR (0.33) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL12783277 | 0.69 | PTAFR (0.48) | EEDPTAFR | |
| SCHEMBL10465075 | 0.68 | CYP2D6 (0.56) | KDM4EALDH1A1GAASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170309832-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9673402-B2 | Platinum metal complexes with divalent groups bridging two ligands | MERCK PATENT GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9181289-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181289-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| EP-2726490-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-04-29 | — | — | EP | disclosed |
| WO-2010115078-A2 | METHOD OF TREATING COGNITIVE IMPAIRMENT | WEBER ECKARD (US) | 2010-10-07 | — | — | WO | disclosed |
| US-7767824-B2 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767824-B2 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| WO-2010077852-A2 | METHOD OF INDUCING CLEAVAGE OF AMYLOID PRECURSOR PROTEIN TO FORM A NOVEL FRAGMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168135-A1 | Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2009107401-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2009-09-03 | — | — | WO | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, GRN | KDM4E 4674/4885ALDH1A1 116/4885GAA 765/4885 |
| US-20100168135-A1 | Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment | APP, APBA1, BACE1 | KDM4E 4780/4885ALDH1A1 3405/4885GAA 1284/4885 |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | KDM4E 4394/4885ALDH1A1 159/4885GAA 373/4885 |
| US-20170309832-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | KDM4E 3816/4885ALDH1A1 3721/4885GAA 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.